FindTrial
Sign In

Matching Placebo for Upadacitinib

DRUG2 trials

Sponsors

Abbvie Deutschland GmbH & Co. KG, AbbVie

Conditions

Crohn's DiseaseHidradenitis Suppurativa

Phase 3

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
CompletedNCT03345836
AbbVieCrohn's Disease
Start: 2017-11-29End: 2021-08-11Updated: 2022-08-15
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RecruitingCTIS2023-503661-28-00
Abbvie Deutschland GmbH & Co. KGHidradenitis Suppurativa
Start: 2023-10-26Target: 542Updated: 2025-09-09

Related Papers

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies
Journal of Gastroenterology2026-08-30
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.
2026-01-01
P0774 Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study
Journal of Crohn s and Colitis2026-01-01
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
2025-11-04
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
Open Access CRIS of the University of Bern2025-11-04
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
2024-09-2414 citations
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease
Inflammatory Bowel Diseases2024-09-045 citations
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn’s Disease
Journal of Crohn s and Colitis2024-06-0513 citations
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
Clinical Gastroenterology and Hepatology2024-03-1519 citations
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
2024-03-1511 citations
P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease
Journal of Crohn s and Colitis2024-01-01
S1160 Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately-to-Severely Active Crohn’s Disease
The American Journal of Gastroenterology2023-10-011 citations
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
New England Journal of Medicine2023-05-24360 citations
P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease
Journal of Crohn s and Colitis2023-01-3031 citations
DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy
Journal of Crohn s and Colitis2023-01-305 citations
OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
Journal of Crohn s and Colitis2023-01-305 citations
P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials
Journal of Crohn s and Colitis2023-01-304 citations
DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
Journal of Crohn s and Colitis2023-01-302 citations
P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Journal of Crohn s and Colitis2023-01-301 citations
P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
Journal of Crohn s and Colitis2023-01-30

1 more papers not shown